We are conducting the ELiSA Study (Evaluation of Lixivaptan In Subjects with ADPKD), a Phase 2 clinical trial that will evaluate the safety, pharmacokinetics and pharmacodynamics of multiple doses of lixivaptan in patients with ADPKD with relatively preserved kidney function (chronic kidney disease stages CKD1 and CKD2) and moderately impaired renal function (CKD3). The study is expected to enroll up to 35 patients at 15 US sites beginning the end of June 2018.

 

For more information about the ELiSA study, please visit the study record at the Clinicaltrials.gov website at this link.